» Articles » PMID: 33964664

Aspirin and Omega-3 Fatty Acid Status Interact in the Prevention of Cardiovascular Diseases in Framingham Heart Study

Overview
Specialty Endocrinology
Date 2021 May 8
PMID 33964664
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The roles of omega-3 (n3) fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] and low-dose aspirin in the primary prevention of ischemic cardiovascular disease (CVD) are controversial. Since omega-3 (n3) fatty acids and aspirin affect cyclooxygenase activity in platelets, there could be a clinically-relevant effect of aspirin combined with a particular n3 fatty acid level present in each individual.

Methods: RBC EPA+DHA, arachidonic acid (AA) and docosapentaenoic acid (DPA) were measured in 2500 participants without known CVD in the Framingham Heart Study. We then tested for interactions with reported aspirin use (1004 reported use and 1494 did not) on CVD outcomes. The median follow-up was 7.2 years.

Results: Having RBC EPA+DHA in the second quintile (4.2-4.9% of total fatty acids) was associated with significantly reduced risk for future CVD events (relative to the first quintile, <4.2%) in those who did not take aspirin (HR 0.54 (0.30, 0.98)), but in those reporting aspirin use, risk was significantly increased (HR 2.16 (1.19, 3.92)) in this quintile. This interaction remained significant when adjusting for confounders. Significant interactions were also present for coronary heart disease and stroke outcomes using the same quintiles. Similar findings were present for EPA and DHA alone but not for DPA and AA.

Conclusions: There is a complex interaction between aspirin use and RBC EPA+DHA levels on CVD outcomes. This suggests that aspirin use may be beneficial in one omega-3 environment but harmful in another, implying that a personalized approach to both aspirin use and omega-3 supplementation may be needed.

Citing Articles

The function of omega-3 polyunsaturated fatty acids in response to cadmium exposure.

Chen Z, Lu Q, Wang J, Cao X, Wang K, Wang Y Front Immunol. 2022; 13:1023999.

PMID: 36248838 PMC: 9558127. DOI: 10.3389/fimmu.2022.1023999.

References
1.
McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

2.
DiChiara J, Bliden K, Tantry U, Hamed M, Antonino M, Suarez T . The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007; 56(12):3014-9. DOI: 10.2337/db07-0707. View

3.
Harris W, Tintle N, Etherton M, Vasan R . Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study. J Clin Lipidol. 2018; 12(3):718-727.e6. PMC: 6034629. DOI: 10.1016/j.jacl.2018.02.010. View

4.
Ridker P . Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?. N Engl J Med. 2018; 379(16):1572-1574. DOI: 10.1056/NEJMe1812000. View

5.
Bhatt D, Steg P, Miller M, Brinton E, Jacobson T, Ketchum S . Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019; 73(22):2791-2802. DOI: 10.1016/j.jacc.2019.02.032. View